HA
CRSP icon

Herold Advisors’s CRISPR Therapeutics CRSP Stock Holding History

Herold Advisors’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-200
Closed -$12.6K – 281
2022
Q1 		$12.6K Buy
+200
New +$12.6K ﹤0.01% 572
2021
Q4 		– Sell
-200
Closed -$22K – 281
2021
Q3 		$22K Buy
+200
New +$25.1K 0.01% 500

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Herold Advisors's CRSP Position: Q2 2022 in Review

Herold Advisors sold out of CRISPR Therapeutics (CRSP) in Q2 2022, closing a stake of 200 shares — an estimated $12.6K sold.

Herold Advisors first reported a position in CRSP in Q3 2021 and held it in 2 quarters. The position peaked at $22K in Q3 2021. 435 funds tracked by Wall St. Rank hold CRSP as of Q2 2022.

  • Herold Advisors reported no remaining CRISPR Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Herold Advisors sold 200 CRISPR Therapeutics shares in Q2 2022, an estimated $12.6K.
  • Herold Advisors first reported a position in CRISPR Therapeutics in Q3 2021 and held it in 2 quarters.
  • Herold Advisors's CRISPR Therapeutics position peaked at $22K in Q3 2021.
  • 435 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2022.

Based on Herold Advisors's 13F filing for Q2 2022, filed 15 Jul 2022.